Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts
Authors
Krebs, Matthew GTarruella, M. M.
Forster, M.
Peguero, J. A.
Clay, T.
Felip, E.
Iams, W.
Roxburgh, P.
de Speville, B. D.
Bajaj, P.
Mueller, C.
Triebel, F.
Issue Date
2022
Metadata
Show full item recordCitation
Krebs MG, Majem Tarruella M, Forster M, Peguero JA, Clay T, Felip E, et al. 11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts. Vol. 33, Annals of Oncology. Elsevier BV; 2022. p. S33.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.02.020Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.02.020Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.02.020